Cantor Fitzgerald Issues Positive Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of $0.12 for the year, up from their prior forecast of $0.05. Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Several other research analysts have also recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. Needham & Company LLC restated a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Esperion Therapeutics has an average rating of "Hold" and an average target price of $6.75.

Remove Ads

Esperion Therapeutics Price Performance

Shares of ESPR traded up $0.01 during mid-day trading on Friday, hitting $1.51. The company's stock had a trading volume of 1,398,618 shares, compared to its average volume of 5,956,761. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.08. The stock has a market capitalization of $297.76 million, a price-to-earnings ratio of -2.37 and a beta of 1.04. Esperion Therapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $3.94.

Institutional Trading of Esperion Therapeutics

A number of hedge funds have recently modified their holdings of the company. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $39,000. Versor Investments LP acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $44,000. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Crestline Management LP acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $63,000. Finally, Summit Wealth Group LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $66,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.